Kane Biotech Inc. (CVE:KNE – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.03 and last traded at C$0.04, with a volume of 4500 shares. The stock had previously closed at C$0.03.
Kane Biotech Price Performance
The stock has a fifty day simple moving average of C$0.03 and a two-hundred day simple moving average of C$0.04. The company has a market cap of C$6.36 million, a PE ratio of -1.75 and a beta of 1.03. The company has a current ratio of 0.45, a quick ratio of 0.39 and a debt-to-equity ratio of -135.17.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Articles
- Five stocks we like better than Kane Biotech
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
